Release Date: 11/1/2022
Expiration Date: 11/1/2023
Learner Notification
*Please note that you must complete the Post Webinar Evaluation (link below) to receive CE credit.
Speakers
Jeremy Lund, PharmD, MS, DABAT, BCCCP, BCPS
Clinical Toxicologist
Sarasota Memorial Healthcare Center
Has disclosed no relevant financial relationships
Kristen Charity "KC" O'Brien, PharmD, DABAT
Clinical Pharmacist
Orlando Regional Medical Center
Has disclosed no relevant financial relationships
Moderators
Alexandra Funk, PharmD, DABAT
Managing Director
Florida Poison Information Center
Has disclosed no relevant financial relationships
Adam Overberg, PharmD, DABAT
Managing Director
Indiana University Health Methodist Hospital
Has disclosed no relevant financial relationships
Description
Drs. Lund and O’Brien will discuss the following articles:
- McMartin K, Brent J. (2022) Analysis of Fomepizole Elimination in Methanol- and Ethylene Glycol-Poisoned Patients. Journal of Medical Toxicology 18:1, pages 19-29.
- Lao YE, Vartdal T, Froeyshov S, Latimer B, Kvaerner C, Mataric M, Holm P, Foreid S, Jacobsen D, McMartin K, Hovda KE. Fomepizole dosing during continuous renal replacement therapy - an observational study. Clin Toxicol (Phila). 2022 Apr;60(4):451-457. doi: 10.1080/15563650.2021.1980581. Epub 2021 Sep 29. PMID: 34585641.
Acknowledgement of In-Kind Commercial Support
No in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Academy of Clinical Toxicology. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM for physicians and 1 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of the activity to meet the deadline for submission to CPE Monitor.
Objectives - After attending this program you should be able to:
- Differentiate between published recommendations for fomepizole dosing in patients receiving different renal replacement strategies
- Describe the pharmacokinetics of fomepizole in CRRT
- Compare fomepizole pharmacokinetics in healthy human subjects and patients with methanol and ethylene glycol poisoning
- Assess the effect of hemodialysis on clearance of fomepizole in methanol- and ethylene glycol-poisoned patients
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.